The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilar of Remicade Market Research Report 2024
Synopsis
A biosimilar of Remicade is a biologic medication that is highly similar to the reference product, Remicade, in terms of safety, efficacy, and quality.
The global Biosimilar of Remicade market was valued at US$ 299000 million in 2023 and is anticipated to reach US$ 491720 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The market for biosimilars of Remicade is driven by the increasing adoption of biosimilar therapies and the need for affordable treatment options for autoimmune diseases. The market's growth is also influenced by the presence of well-established regulatory pathways for biosimilar approval and the entry of multiple biosimilar manufacturers into the market.
This report aims to provide a comprehensive presentation of the global market for Biosimilar of Remicade, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar of Remicade.
Report Scope
The Biosimilar of Remicade market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar of Remicade market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar of Remicade companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar of Remicade companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A biosimilar of Remicade is a biologic medication that is highly similar to the reference product, Remicade, in terms of safety, efficacy, and quality.
The global Biosimilar of Remicade market was valued at US$ 299000 million in 2023 and is anticipated to reach US$ 491720 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The market for biosimilars of Remicade is driven by the increasing adoption of biosimilar therapies and the need for affordable treatment options for autoimmune diseases. The market's growth is also influenced by the presence of well-established regulatory pathways for biosimilar approval and the entry of multiple biosimilar manufacturers into the market.
This report aims to provide a comprehensive presentation of the global market for Biosimilar of Remicade, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar of Remicade.
Report Scope
The Biosimilar of Remicade market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilar of Remicade market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar of Remicade companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilar of Remicade companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilar of Remicade Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Other
1.3 Market by Application
1.3.1 Global Biosimilar of Remicade Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilar of Remicade Market Perspective (2019-2030)
2.2 Biosimilar of Remicade Growth Trends by Region
2.2.1 Global Biosimilar of Remicade Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilar of Remicade Historic Market Size by Region (2019-2024)
2.2.3 Biosimilar of Remicade Forecasted Market Size by Region (2025-2030)
2.3 Biosimilar of Remicade Market Dynamics
2.3.1 Biosimilar of Remicade Industry Trends
2.3.2 Biosimilar of Remicade Market Drivers
2.3.3 Biosimilar of Remicade Market Challenges
2.3.4 Biosimilar of Remicade Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilar of Remicade Players by Revenue
3.1.1 Global Top Biosimilar of Remicade Players by Revenue (2019-2024)
3.1.2 Global Biosimilar of Remicade Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilar of Remicade Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilar of Remicade Revenue
3.4 Global Biosimilar of Remicade Market Concentration Ratio
3.4.1 Global Biosimilar of Remicade Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilar of Remicade Revenue in 2023
3.5 Biosimilar of Remicade Key Players Head office and Area Served
3.6 Key Players Biosimilar of Remicade Product Solution and Service
3.7 Date of Enter into Biosimilar of Remicade Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilar of Remicade Breakdown Data by Type
4.1 Global Biosimilar of Remicade Historic Market Size by Type (2019-2024)
4.2 Global Biosimilar of Remicade Forecasted Market Size by Type (2025-2030)
5 Biosimilar of Remicade Breakdown Data by Application
5.1 Global Biosimilar of Remicade Historic Market Size by Application (2019-2024)
5.2 Global Biosimilar of Remicade Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilar of Remicade Market Size (2019-2030)
6.2 North America Biosimilar of Remicade Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilar of Remicade Market Size by Country (2019-2024)
6.4 North America Biosimilar of Remicade Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilar of Remicade Market Size (2019-2030)
7.2 Europe Biosimilar of Remicade Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilar of Remicade Market Size by Country (2019-2024)
7.4 Europe Biosimilar of Remicade Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilar of Remicade Market Size (2019-2030)
8.2 Asia-Pacific Biosimilar of Remicade Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilar of Remicade Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilar of Remicade Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilar of Remicade Market Size (2019-2030)
9.2 Latin America Biosimilar of Remicade Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilar of Remicade Market Size by Country (2019-2024)
9.4 Latin America Biosimilar of Remicade Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilar of Remicade Market Size (2019-2030)
10.2 Middle East & Africa Biosimilar of Remicade Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilar of Remicade Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilar of Remicade Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Biosimilar of Remicade Introduction
11.1.4 Roche Revenue in Biosimilar of Remicade Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Biosimilar of Remicade Introduction
11.2.4 Amgen Revenue in Biosimilar of Remicade Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Biosimilar of Remicade Introduction
11.3.4 AbbVie Revenue in Biosimilar of Remicade Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Sanofi-Aventis
11.4.1 Sanofi-Aventis Company Detail
11.4.2 Sanofi-Aventis Business Overview
11.4.3 Sanofi-Aventis Biosimilar of Remicade Introduction
11.4.4 Sanofi-Aventis Revenue in Biosimilar of Remicade Business (2019-2024)
11.4.5 Sanofi-Aventis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Biosimilar of Remicade Introduction
11.5.4 Johnson & Johnson Revenue in Biosimilar of Remicade Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Pfizer
11.6.1 Pfizer Company Detail
11.6.2 Pfizer Business Overview
11.6.3 Pfizer Biosimilar of Remicade Introduction
11.6.4 Pfizer Revenue in Biosimilar of Remicade Business (2019-2024)
11.6.5 Pfizer Recent Development
11.7 Novo Nordisk
11.7.1 Novo Nordisk Company Detail
11.7.2 Novo Nordisk Business Overview
11.7.3 Novo Nordisk Biosimilar of Remicade Introduction
11.7.4 Novo Nordisk Revenue in Biosimilar of Remicade Business (2019-2024)
11.7.5 Novo Nordisk Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Detail
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Biosimilar of Remicade Introduction
11.8.4 Eli Lilly Revenue in Biosimilar of Remicade Business (2019-2024)
11.8.5 Eli Lilly Recent Development
11.9 Novartis
11.9.1 Novartis Company Detail
11.9.2 Novartis Business Overview
11.9.3 Novartis Biosimilar of Remicade Introduction
11.9.4 Novartis Revenue in Biosimilar of Remicade Business (2019-2024)
11.9.5 Novartis Recent Development
11.10 Merck
11.10.1 Merck Company Detail
11.10.2 Merck Business Overview
11.10.3 Merck Biosimilar of Remicade Introduction
11.10.4 Merck Revenue in Biosimilar of Remicade Business (2019-2024)
11.10.5 Merck Recent Development
11.11 3sbio
11.11.1 3sbio Company Detail
11.11.2 3sbio Business Overview
11.11.3 3sbio Biosimilar of Remicade Introduction
11.11.4 3sbio Revenue in Biosimilar of Remicade Business (2019-2024)
11.11.5 3sbio Recent Development
11.12 Changchun High Tech
11.12.1 Changchun High Tech Company Detail
11.12.2 Changchun High Tech Business Overview
11.12.3 Changchun High Tech Biosimilar of Remicade Introduction
11.12.4 Changchun High Tech Revenue in Biosimilar of Remicade Business (2019-2024)
11.12.5 Changchun High Tech Recent Development
11.13 CP Guojian
11.13.1 CP Guojian Company Detail
11.13.2 CP Guojian Business Overview
11.13.3 CP Guojian Biosimilar of Remicade Introduction
11.13.4 CP Guojian Revenue in Biosimilar of Remicade Business (2019-2024)
11.13.5 CP Guojian Recent Development
11.14 Biotech
11.14.1 Biotech Company Detail
11.14.2 Biotech Business Overview
11.14.3 Biotech Biosimilar of Remicade Introduction
11.14.4 Biotech Revenue in Biosimilar of Remicade Business (2019-2024)
11.14.5 Biotech Recent Development
11.15 Gelgen
11.15.1 Gelgen Company Detail
11.15.2 Gelgen Business Overview
11.15.3 Gelgen Biosimilar of Remicade Introduction
11.15.4 Gelgen Revenue in Biosimilar of Remicade Business (2019-2024)
11.15.5 Gelgen Recent Development
11.16 Innovent
11.16.1 Innovent Company Detail
11.16.2 Innovent Business Overview
11.16.3 Innovent Biosimilar of Remicade Introduction
11.16.4 Innovent Revenue in Biosimilar of Remicade Business (2019-2024)
11.16.5 Innovent Recent Development
11.17 Dong Bao
11.17.1 Dong Bao Company Detail
11.17.2 Dong Bao Business Overview
11.17.3 Dong Bao Biosimilar of Remicade Introduction
11.17.4 Dong Bao Revenue in Biosimilar of Remicade Business (2019-2024)
11.17.5 Dong Bao Recent Development
11.18 Ganlee
11.18.1 Ganlee Company Detail
11.18.2 Ganlee Business Overview
11.18.3 Ganlee Biosimilar of Remicade Introduction
11.18.4 Ganlee Revenue in Biosimilar of Remicade Business (2019-2024)
11.18.5 Ganlee Recent Development
11.19 United Laboratories
11.19.1 United Laboratories Company Detail
11.19.2 United Laboratories Business Overview
11.19.3 United Laboratories Biosimilar of Remicade Introduction
11.19.4 United Laboratories Revenue in Biosimilar of Remicade Business (2019-2024)
11.19.5 United Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
